Clinical Trial Update: Regression of Fatty Heart by Valsartan Therapy [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating valsartan for regression of fatty heart in metabolic syndrome was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome

Drugs mentioned

• DIOVAN (valsartan)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Metabolic Syndrome, Lipotoxicity | Phase 4 | Status: WITHDRAWN